Incorporating SSTR4 as a biomarker could facilitate early detection, disease monitoring, and evaluation of cognitive-enhancing therapies, enabling personalized treatment approaches and potentially improving long-term outcomes for individuals with schizophrenia. The gene discussed is SSTR4; the disease is schizophrenia.